Cullinan Associates Inc. Has $746,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Cullinan Associates Inc. trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 3.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,675 shares of the company’s stock after selling 325 shares during the quarter. Cullinan Associates Inc.’s holdings in Novo Nordisk A/S were worth $746,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of NVO. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the third quarter worth about $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter worth about $48,000. Dunhill Financial LLC increased its position in shares of Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after acquiring an additional 311 shares in the last quarter. Finally, Albion Financial Group UT increased its position in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.1 %

NVO opened at $82.60 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $370.65 billion, a price-to-earnings ratio of 26.73, a PEG ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company’s 50-day moving average price is $93.12 and its two-hundred day moving average price is $112.54.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.